deploy: cbeeff6

sab/index.html

@@ -10,7 +10,7 @@
 program, which led to the development of pimodivir, a first in class PB2 inhibitor; she was awarded
 the Gertrude Elion Memorial Award in 2020 by the International Society for Antiviral Research.
 Ann founded Trek Therapeutics to develop affordable HCV treatments; and was the EVP of R&D at
-Dewpoint Therapeutics. She is currently the EVP of Research at Pardes Biosciences.<br>Ann is a co-author or inventor on numerous publications and patents and received her BA in Biology
+Dewpoint Therapeutics. She is currently Principal at Kwong Pharma Consulting, LLC.<br>Ann is a co-author or inventor on numerous publications and patents and received her BA in Biology
 and PhD in virology from the University of Chicago.</i></p></div></div><hr><div class="row gutters"><div class="col col-2"><img src=../members/img/people/lisa-purcell.jpg></div><div class="col col-9"><h4><b>Lisa Purcell</b></h4><p><b>External Scientific Advisory Board Member</b><br>Senior Vice President of Microbiology and Virology, Vir Biotechnology<br>web: <a href=https://www.linkedin.com/in/lisa-purcell-phd-854a3572/>https://www.linkedin.com/in/lisa-purcell-phd-854a3572/</a><br><i>Lisa Purcell, Ph.D. has served as the Senior Vice President of Microbiology and Virology since December 2020. Dr. Purcell’s career has been dedicated to the development of therapies within the immunology and infectious disease areas, including those for SARS-CoV-2/COVID-19. From July 2008 to December 2020, Dr. Purcell worked in both the clinical and nonclinical areas at Regeneron Pharmaceuticals focusing on the development of drugs for infectious disease, allergy and inflammation. Dr. Purcell received her B.Sc. with Honors in Biology and M.Sc. in Ecotoxicology from the University of Prince Edward Island, her Ph.D. in Parasitology from McGill University and completed her postdoctoral training at Columbia University Vagelos College of Physicians and Surgeons.</i></p></div></div><hr><div class="row gutters"><div class="col col-2"><img src=../members/img/people/wendy-young.jpg></div><div class="col col-9"><h4><b>Wendy Young</b></h4><p><b>External Scientific Advisory Board Member</b><br>Biopharma Executive, Scientific Advisor, Board Member, MPM Capital<br>web: <a href=https://www.linkedin.com/in/wendy-young-65a1572/>https://www.linkedin.com/in/wendy-young-65a1572/</a><br><i>Distinguished medicinal chemist and pharma executive. Wendy was formerly Senior Vice President at Genentech leading drug discovery. Under her leadership, more than 25 clinical candidates, in the areas of oncology, immunology, neurology, and anti-infectives progressed into development. Wendy is the inventor of fenebrutinib which is in Phase 3 trials for multiple sclerosis. Currently, Wendy is the CEO of a biotech company in stealth mode, Director and/or Scientific Advisory Board Member of several private biotechs, an Associate Editor of the Journal of Medicinal Chemistry and an advisor at GV (Google Ventures). Dr. Young brings expertise in medicinal chemistry strategy and business development to the SAB.</i></p></div></div><hr></ul><h2>Internal Scientific Advisory Board (SAB) Members</h2><ul><div class="row gutters"><div class="col col-2"><img src=../members/img/people/john-chodera.jpg></div><div class="col col-9"><h4><b>John D. Chodera</b>
 <a href=http://twitter.com/jchodera><img width=20 src=../members/img/icons/twitter.png></a>
 <a href=http://github.com/jchodera><img width=20 src=../members/img/icons/github.png></a></h4><p><b>Principal Investigator; Co-Investigator: Hit-to-Lead; Co-Investigator: Lead Optimization</b><br>Associate Member, Sloan Kettering Institute<br>web: <a href=http://choderalab.org>http://choderalab.org</a><br>ORCID: <a href=https://orcid.org/0000-0003-0542-119X>0000-0003-0542-119X</a>